Background: Follow‑up of curatively treated primary breast cancer patients consists of surveillance and aftercare and is currently mostly the same for all patients. A more personalized approach, based on patients’ individual risk of recurrence and personal needs and preferences, may reduce patient burden and reduce (healthcare) costs. The NABOR study will examine the (cost‑)effectiveness of personalized surveillance (PSP) and personalized aftercare plans (PAP) on patient‑reported cancer worry, self‑rated and overall quality of life and (cost‑)effectiveness. Methods: A prospective multicenter multiple interrupted time series (MITs) design is being used. In this design, 10 participating hospitals will be observed for a period of eighteen months, while they ‑stepwise‑ will transit from care as usual to PSPs and PAPs. The PSP contains decisions on the surveillance trajectory based on individual risks and needs, assessed with the ‘Breast Cancer Surveillance Decision Aid’ including the INFLUENCE prediction tool. The PAP contains decisions on the aftercare trajectory based on individual needs and preferences and available care resources, which decision‑making is supported by a patient decision aid. Patients are non‑metastasized female primary breast cancer patients (N= 1040) who are curatively treated and start follow‑up care. Patient reported outcomes will be measured at five points in time during two years of follow‑up care (starting about one year after treatment and every six months thereafter). In addition, data on diagnostics and hospital visits from patients’ Electronical Health Records (EHR) will be gathered. Primary outcomes are patient‑reported cancer worry (Cancer Worry Scale) and over‑all quality of life (as assessed with EQ‑VAS score). Secondary outcomes include health care costs and resource use, health‑related quality of life (as measured with EQ5D‑5L/SF‑12/EORTC‑QLQ‑C30), risk perception, shared decision‑making, patient satisfaction, societal participation, and cost‑effectiveness. Next, the uptake and appreciation of personalized plans and patients’ experiences of their decision‑making process will be evaluated. Discussion: This study will contribute to insight in the (cost‑)effectiveness of personalized follow‑up care and contributes to development of uniform evidence‑based guidelines, stimulating sustainable implementation of personalized surveillance and aftercare plans. Trial registration: Study sponsor: ZonMw. Retrospectively registered at ClinicalTrials.gov (2023), ID: NCT05975437.
MULTIFILE
The aim of this paper is to design and test a smartphone application which supports personalized running experiences for less experienced runners. As a result of a multidisciplinary three-step design approach Inspirun was developed. Inspirun is a personalized running-application for Android smartphones that aims to fill the gap between running on your own (static) schedule, and having a personal trainer that accommodates the schedule to your needs and profile. With the use of GPS and Bluetooth heart rate monitor support, a user's progress gets tracked. The application adjusts the training schedule after each training session, motivating the runner without a real life coach. Results from three user studies are promising; participants were very satisfied with the personalized approach, both in the profiling and de adaptation of their training scheme.
DOCUMENT
In February 2017, seven partners signed a contract to collaborate on a project called the Healthy Workplace. Measuremen, Menzis, Health2Work, ENGIE, Planon, and Hanzehogeschool Groningen are dedicated to make the regular workplace a healthy workplace. Health is of primary importance for both the employee and employer. Employees want to be healthy, feel energized and reach an old age. While every organization wishes for the benefits of energized and healthy employees by increased engagement and less absenteeism.
LINK
Organs-on-chips (OoCs) worden steeds belangrijker voor geneesmiddelonderzoek. Het kweken van miniatuurorganen in microfluïdische chips creëert een systeem waarmee geneesmiddelonderzoekers efficiënt geneesmiddelen kunnen testen. OoCs kunnen in de toekomst een belangrijk instrument voor personalized medicine worden: door het kweken van patiëntmateriaal in OoCs kan dan worden bepaald welke interventies voor specifieke patiënten werken en veilig zijn. In de huidige praktijk worden cellulaire veranderingen in OoCs na blootstelling aan een geneesmiddel doorgaans gevolgd met visualisatietechnieken, waarmee alleen effecten van geneesmiddelen kunnen worden waargenomen. Voor bepaling van de voor geneesmiddelonderzoek cruciale parameters absorptie, distributie, metabolisme en excretie (ADME) is het noodzakelijk om de concentraties van geneesmiddelen en hun relevante metabolieten te meten. Het doel van AC/OC is dit mogelijk te maken door het ontwikkelen van analytisch-chemische technieken, gebaseerd op vloeistofchromatografie gekoppeld met massaspectrometrie (LC-MS). Hiermee kunnen ontwikkelaars van OoCs (de eindgebruikers van AC/OC) de voordelen van hun producten voor geneesmiddelonderzoek beter onderbouwen. Dit project bouwt voort op twee KIEM-projecten, waarin enkele veelbelovende analytisch-chemische technieken succesvol zijn verkend. In AC/OC zullen wij: 1. analytisch-chemische methodes ontwikkelen die geschikt zijn om een breed scala aan geneesmiddelen en metabolieten te bepalen in meerdere types OoCs; 2. deze methodes verbeteren, zodat de analyse geautomatiseerd, sneller en gevoeliger wordt; 3. de potentie van deze methodes voor geneesmiddelonderzoek met OoCs demonsteren door ze toe te passen op enkele praktijkvraagstukken. Het OoC-veld ontwikkelt zich razendsnel en Nederland (georganiseerd binnen OoC-consortium hDMT) speelt daarin een belangrijke rol. AC/OC verbindt kennis en expertise op het gebied van analytische chemie, OoCs, celkweek en geneesmiddelonderzoek. Hierdoor kan AC/OC een bijdrage leveren aan sneller en betrouwbaarder geneesmiddelonderzoek. Met de ontwikkeling van een minor ‘OoC-Technology’, waarin we de onderzoeksresultaten vertalen naar onderwijs, spelen we in op de behoefte aan professionals met kennis, ervaring en belangstelling op het gebied van OoCs.
Alcohol use disorder (AUD) is a major problem. In the USA alone there are 15 million people with an AUD and more than 950,000 Dutch people drink excessively. Worldwide, 3-8% of all deaths and 5% of all illnesses and injuries are attributable to AUD. Care faces challenges. For example, more than half of AUD patients relapse within a year of treatment. A solution for this is the use of Cue-Exposure-Therapy (CET). Clients are exposed to triggers through objects, people and environments that arouse craving. Virtual Reality (VRET) is used to experience these triggers in a realistic, safe, and personalized way. In this way, coping skills are trained to counteract alcohol cravings. The effectiveness of VRET has been (clinically) proven. However, the advent of AR technologies raises the question of exploring possibilities of Augmented-Reality-Exposure-Therapy (ARET). ARET enjoys the same benefits as VRET (such as a realistic safe experience). But because AR integrates virtual components into the real environment, with the body visible, it presumably evokes a different type of experience. This may increase the ecological validity of CET in treatment. In addition, ARET is cheaper to develop (fewer virtual elements) and clients/clinics have easier access to AR (via smartphone/tablet). In addition, new AR glasses are being developed, which solve disadvantages such as a smartphone screen that is too small. Despite the demand from practitioners, ARET has never been developed and researched around addiction. In this project, the first ARET prototype is developed around AUD in the treatment of alcohol addiction. The prototype is being developed based on Volumetric-Captured-Digital-Humans and made accessible for AR glasses, tablets and smartphones. The prototype will be based on RECOVRY, a VRET around AUD developed by the consortium. A prototype test among (ex)AUD clients will provide insight into needs and points for improvement from patient and care provider and into the effect of ARET compared to VRET.
Alcohol Use Disorder (AUD) involves uncontrollable drinking despite negative consequences, a challenge amplified in festivals. ARise is a project using Augmented Reality (AR) to prevent AUD by helping festival visitors refuse alcohol and other substances. Based on the first Augmented Reality Exposure Therapy (ARET) for clinical AUD treatment, ARise uses a smartphone app with AR glasses to project virtual humans that tempt visitors to drink alcohol. Users interact in a safe and personalized way with these virtual humans through phone, voice, and gesture interactions. The project gathers festival feedback on user experience, awareness, usability, and potential expansion to other substances.Societal issueHelping treatment of addiction and stimulate social inclusion.Benefit to societyMore people less patients: decrease health cost and increase in inclusion and social happiness.Collaborative partnersNovadic-Kentron, Thalamusa
Lectoraat, onderdeel van HAS green academy
